Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
Angiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/3/1369 |
| _version_ | 1827759796597555200 |
|---|---|
| author | Collin Vandemark Jimmy Nguyen Zhi-Qing Zhao |
| author_facet | Collin Vandemark Jimmy Nguyen Zhi-Qing Zhao |
| author_sort | Collin Vandemark |
| collection | DOAJ |
| description | Angiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases. |
| first_indexed | 2024-03-11T09:32:38Z |
| format | Article |
| id | doaj.art-ac0aa1f127fb4977b77b35eaa34e579d |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-11T09:32:38Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-ac0aa1f127fb4977b77b35eaa34e579d2023-11-16T17:31:29ZengMDPI AGMolecules1420-30492023-02-01283136910.3390/molecules28031369Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental UpdateCollin Vandemark0Jimmy Nguyen1Zhi-Qing Zhao2Cardiovascular Research Laboratory, Mercer University School of Medicine, Savannah, GA 31404, USACardiovascular Research Laboratory, Mercer University School of Medicine, Savannah, GA 31404, USACardiovascular Research Laboratory, Mercer University School of Medicine, Savannah, GA 31404, USAAngiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases.https://www.mdpi.com/1420-3049/28/3/1369angiotensin IIglucagon-like peptide 1hypertensionheart failureliraglutidemyocardial fibrosis |
| spellingShingle | Collin Vandemark Jimmy Nguyen Zhi-Qing Zhao Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update Molecules angiotensin II glucagon-like peptide 1 hypertension heart failure liraglutide myocardial fibrosis |
| title | Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update |
| title_full | Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update |
| title_fullStr | Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update |
| title_full_unstemmed | Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update |
| title_short | Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update |
| title_sort | cardiovascular protection with a long acting glp 1 receptor agonist liraglutide an experimental update |
| topic | angiotensin II glucagon-like peptide 1 hypertension heart failure liraglutide myocardial fibrosis |
| url | https://www.mdpi.com/1420-3049/28/3/1369 |
| work_keys_str_mv | AT collinvandemark cardiovascularprotectionwithalongactingglp1receptoragonistliraglutideanexperimentalupdate AT jimmynguyen cardiovascularprotectionwithalongactingglp1receptoragonistliraglutideanexperimentalupdate AT zhiqingzhao cardiovascularprotectionwithalongactingglp1receptoragonistliraglutideanexperimentalupdate |